170 related articles for article (PubMed ID: 15777244)
1. TNF-related apoptosis-inducing ligand (TRAIL) as a pro-apoptotic signal transducer with cancer therapeutic potential.
Fiorucci G; Vannucchi S; Chiantore MV; Percario ZA; Affabris E; Romeo G
Curr Pharm Des; 2005; 11(7):933-44. PubMed ID: 15777244
[TBL] [Abstract][Full Text] [Related]
2. Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.
Mitsiades N; Mitsiades CS; Poulaki V; Anderson KC; Treon SP
Expert Opin Investig Drugs; 2001 Aug; 10(8):1521-30. PubMed ID: 11772267
[TBL] [Abstract][Full Text] [Related]
3. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy.
Wajant H; Pfizenmaier K; Scheurich P
Apoptosis; 2002 Oct; 7(5):449-59. PubMed ID: 12207178
[TBL] [Abstract][Full Text] [Related]
4. TRAIL: a potential agent for cancer therapy.
Shi J; Zheng D; Man K; Fan ST; Xu R
Curr Mol Med; 2003 Dec; 3(8):727-36. PubMed ID: 14682494
[TBL] [Abstract][Full Text] [Related]
5. License to kill tumors: how much hope is justified for trail?
Frank S; Ebert AD
Curr Pharm Des; 2001 Nov; 7(16):1689-701. PubMed ID: 11562306
[TBL] [Abstract][Full Text] [Related]
6. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Sayers TJ; Murphy WJ
Cancer Immunol Immunother; 2006 Jan; 55(1):76-84. PubMed ID: 15864587
[TBL] [Abstract][Full Text] [Related]
7. TRAIL and chemotherapeutic drugs in cancer therapy.
Wu XX; Ogawa O; Kakehi Y
Vitam Horm; 2004; 67():365-83. PubMed ID: 15110186
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
Poulaki V; Mitsiades CS; Kotoula V; Tseleni-Balafouta S; Ashkenazi A; Koutras DA; Mitsiades N
Am J Pathol; 2002 Aug; 161(2):643-54. PubMed ID: 12163389
[TBL] [Abstract][Full Text] [Related]
10. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
11. TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies.
Secchiero P; Vaccarezza M; Gonelli A; Zauli G
Curr Pharm Des; 2004; 10(29):3673-81. PubMed ID: 15579063
[TBL] [Abstract][Full Text] [Related]
12. Steering anti-cancer drugs away from the TRAIL.
Nagata S
Nat Med; 2000 May; 6(5):502-3. PubMed ID: 10802698
[No Abstract] [Full Text] [Related]
13. TRAIL and apoptosis induction by TNF-family death receptors.
Wang S; El-Deiry WS
Oncogene; 2003 Nov; 22(53):8628-33. PubMed ID: 14634624
[TBL] [Abstract][Full Text] [Related]
14. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo.
Shankar S; Chen X; Srivastava RK
Prostate; 2005 Feb; 62(2):165-86. PubMed ID: 15389801
[TBL] [Abstract][Full Text] [Related]
15. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
He Q; Luo X; Huang Y; Sheikh MS
Oncogene; 2002 Sep; 21(39):6032-40. PubMed ID: 12203115
[TBL] [Abstract][Full Text] [Related]
16. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.
He Q; Huang Y; Sheikh MS
Oncogene; 2004 Apr; 23(14):2554-8. PubMed ID: 14691451
[TBL] [Abstract][Full Text] [Related]
18. TRAIL and malignant glioma.
Hawkins CJ
Vitam Horm; 2004; 67():427-52. PubMed ID: 15110189
[TBL] [Abstract][Full Text] [Related]
19. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
20. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.
Cretney E; Shanker A; Yagita H; Smyth MJ; Sayers TJ
Immunol Cell Biol; 2006 Feb; 84(1):87-98. PubMed ID: 16405656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
